Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX

Excessive secretion of glucagon, a functional insulin antagonist, significantly contributes to hyperglycemia. Glucagon exerts its physiological functions through activation of the glucagon receptor (GCGR). Inhibition of GCGR activity represents a potential therapeutic approach for reducing excess glucose production in diabetes mellitus. Aptamers are short DNA or RNA oligonucleotides evolved from systematic evolution of ligands by exponential enrichment (SELEX). Here, we have successfully selected a DNA aptamer against GCGR by cell-SELEX, which can specifically bind membrane protein of CHO-GCGR cells with a Kd of 52.7 ± 5.1 nM. Aptamer-mediated pull-down and gcgr knockdown assay verified that GCGR was the target of aptamer GR-3. Binding analysis revealed that GR-3 could recognize other cells with different affinity according to the level of GCGR protein expressed in these cells. Hepatic tissue imaging suggested that GR-3 could bind the cell membrane of hepatic tissues. With the advantages of small size, high binding affinity, good stability, lack of immunogenicity, and easy synthesis, aptamer GR-3 against GCGR can be a promising tool with the potential to attenuate hyperglycemia in diabetes mellitus.

[1]  L. Cerchia,et al.  Targeting Axl with an high-affinity inhibitory aptamer. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  John O Trent,et al.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. , 2009, Experimental and molecular pathology.

[3]  J. Holst,et al.  Glucagon antagonism as a potential therapeutic target in type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[4]  Katherine A. Winters,et al.  Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible α-Cell Hyperplasia and Hyperglucagonemia , 2009, Journal of Pharmacology and Experimental Therapeutics.

[5]  D. Shangguan,et al.  Generating Cell Targeting Aptamers for Nanotheranostics Using Cell-SELEX , 2016, Theranostics.

[6]  A. Cherrington,et al.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. , 2012, The Journal of clinical investigation.

[7]  Jun Liu,et al.  Recent developments in protein and cell-targeted aptamer selection and applications. , 2011, Current medicinal chemistry.

[8]  M. J. Charron,et al.  Metabolic manifestations of insulin deficiency do not occur without glucagon action , 2012, Proceedings of the National Academy of Sciences.

[9]  H. Dehghani,et al.  Generation of an enriched pool of DNA aptamers for an HER2‐overexpressing cell line selected by Cell SELEX , 2011, Biotechnology and applied biochemistry.

[10]  D. Shangguan,et al.  Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound Immunoglobin Heavy Mu Chain in Burkitt's Lymphoma Cells*S , 2007, Molecular & Cellular Proteomics.

[11]  Xiaobing Zhang,et al.  CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX , 2016, Oncotarget.

[12]  Yoshikazu Nakamura,et al.  Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface. , 2006, Biochimie.

[13]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[14]  N. Janjić,et al.  Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. , 1999, The American journal of pathology.

[15]  J. Gerich,et al.  The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. , 2007, Endocrine reviews.

[16]  Zilong Zhao,et al.  Nucleic acid aptamers: an emerging frontier in cancer therapy. , 2012, Chemical communications.

[17]  F. Ducongé,et al.  From Ugly Duckling to Swan: Unexpected Identification from Cell-SELEX of an Anti-Annexin A2 Aptamer Targeting Tumors , 2014, PloS one.

[18]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[19]  F J Grant,et al.  Expression cloning and signaling properties of the rat glucagon receptor. , 1993, Science.

[20]  N. Porksen,et al.  Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. , 2004, The Journal of clinical investigation.

[21]  Ke Chen,et al.  Exopolysaccharide from Trichoderma pseudokoningii induces macrophage activation. , 2016, Carbohydrate polymers.

[22]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[23]  Silvia Catuogno,et al.  Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  L. Gold,et al.  A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  W. Duan,et al.  Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. , 2013, Analytical chemistry.

[26]  Bo Liu,et al.  Adipo8, a high-affinity DNA aptamer, can differentiate among adipocytes and inhibit intracellular lipid accumulation in vitro , 2015, Science China Chemistry.

[27]  A. Consoli.  Role of Liver in Pathophysiology of NIDDM , 1992, Diabetes Care.

[28]  Xingmei Zhang,et al.  Cell-SELEX Aptamer for Highly Specific Radionuclide Molecular Imaging of Glioblastoma In Vivo , 2014, PloS one.

[29]  S. Qureshi,et al.  Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice , 2011, Diabetologia.

[30]  J. Treadway,et al.  Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes , 2011, BMC Genomics.

[31]  Bei B. Zhang,et al.  Glucagon and regulation of glucose metabolism. , 2003, American journal of physiology. Endocrinology and metabolism.

[32]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[33]  Kyoung-Jin Oh,et al.  Identification of DNA Aptamers toward Epithelial Cell Adhesion Molecule via Cell-SELEX , 2014, Molecules and cells.

[34]  W. Tan,et al.  Selection of Aptamers Specific for Adipose Tissue , 2012, PloS one.

[35]  R. Burcelin,et al.  Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. , 1996, Diabetes & metabolism.

[36]  C. Yang,et al.  Using DNA Aptamer Probe for Immunostaining of Cancer Frozen Tissues , 2014, Analytical chemistry.

[37]  Weihong Tan,et al.  Cell-specific aptamer probes for membrane protein elucidation in cancer cells. , 2008, Journal of proteome research.

[38]  Silvia Catuogno,et al.  Targeting Insulin Receptor with a Novel Internalizing Aptamer , 2016, Molecular therapy. Nucleic acids.

[39]  S. M. Taghdisi,et al.  Development of RNA aptamers as molecular probes for HER2+ breast cancer study using cell-SELEX , 2015, Iranian journal of basic medical sciences.

[40]  Siqing Shan,et al.  Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Weihong Tan,et al.  DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition , 2015, Theranostics.

[42]  M. Michael,et al.  Glucagon as a target for the treatment of Type 2 diabetes , 2005, Expert opinion on therapeutic targets.

[43]  S. Sell,et al.  A Mixed Mirror-image DNA/RNA Aptamer Inhibits Glucagon and Acutely Improves Glucose Tolerance in Models of Type 1 and Type 2 Diabetes , 2013, The Journal of Biological Chemistry.

[44]  Weihong Tan,et al.  Identification of Cell Membrane Protein Stress-Induced Phosphoprotein 1 as a Potential Ovarian Cancer Biomarker Using Aptamers Selected by Cell Systematic Evolution of Ligands by Exponential Enrichment , 2014, Analytical chemistry.

[45]  V. Ding,et al.  Discovery of potent, orally active benzimidazole glucagon receptor antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[46]  HighWire Press,et al.  The journal of pharmacology and experimental therapeutics , 1909 .

[47]  A D Ellington,et al.  Aptamers as therapeutic and diagnostic reagents: problems and prospects. , 1997, Current opinion in chemical biology.

[48]  D. Shangguan,et al.  Development of DNA aptamers using Cell-SELEX , 2010, Nature Protocols.

[49]  Katherine A. Winters,et al.  Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys , 2009, Journal of Pharmacology and Experimental Therapeutics.

[50]  B. Monia,et al.  Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. , 2004, Diabetes.

[51]  B. Shen,et al.  Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment. , 2003, Journal of biotechnology.

[52]  Tao Wang,et al.  RNA aptamers targeting cancer stem cell marker CD133. , 2013, Cancer letters.

[53]  W. Tompson,et al.  Problems and Prospects: , 2020, Jewish Christianity.

[54]  D. Shangguan,et al.  Facile Discovery of Cell-Surface Protein Targets of Cancer Cell Aptamers* , 2015, Molecular & Cellular Proteomics.

[55]  Chun-Wei Peng,et al.  Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers , 2016, Oncotarget.

[56]  Fang Wang,et al.  DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro , 2013, Acta Pharmacologica Sinica.

[57]  Ting Fu,et al.  Using aptamers to elucidate esophageal cancer clinical samples , 2015, Scientific Reports.